Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study is to compare the effects of Liraglutide and Metformin alone or combined treatment on the cardiac function in T2DM patients complicated with CAD. METHODS: 120 T2DM patients were included at Endocrinology Department of Tianjin First Center Hospital (Tianjin, China) from April 2012 to September 2013. The study contained two sections. Section 1: 30 patients in group 1 was treated with Liraglutide (Novo Nordisk) (1.2 mg/d), and 30 patients in group 2 with Metformin (Shiguibao) (1500 mg/d) for 24 weeks. Section 2: 30 patients in group1 was treated with Liraglutide (1.8 mg/d) and 30 in group 2 with Liraglutide (1.2 mg/d) plus Metformin (1500 mg/d) for 24 weeks. Fasting blood glucose (FBG), postprandial glucose (PPG), glycated hemoglobin (HbA1c), body mass index (BMI), blood pressure (BP), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), C reactive protein (CRP), left ventricular end-diastolic diameter (LVEDD), ejection fraction (EF) and the ratio of early (E) to late (A) ventricular filling velocities (E/A ratio) were measured before and after the 24-week treatment. RESULTS: After 24-week treatment, when blood glucose level was controlled in 4 groups, Liraglutide alone treatment showed better improvements than on all measuring except TG in Section 1, however, combined treatment of Liraglutide and Metformin showed better improvements on all measuring except BMI, TG and BP in Section 2. CONCLUSIONS: With similar glycemic control, the Liraglutide (1.2 mg/d) monotherapy showed the better effects than either Metformin alone, or combination of Liraglutide and Metformin on lipid metabolism and cardiovascular function. TRIAL REGISTRATION: This trial was registered at Chinese Clinical Trial Registry ( chictr.org.cn ) # ChiCTR-IPR-16008578 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“The glucoselowering property alone cannot account for cardiovascular benefit [26].”
BackgroundPower failure: why small sample size undermines the reliability of neuroscience
Button, K. S., Ioannidis, J. P. A., Mokrysz, C., Nosek, B. A., Flint, J., Robinson, E. S. J., & Munafò, M. R. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3475 · Cited by 7,641 · cited 2×
“The ability of Metformin to reduce hepatic glucose production and increase skeletal muscle glucose uptake has made it as one of the major first-line therapies for T2DM [22, 23].”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“A recent study of 36month LEADER trial revealed that Liraglutide improved cardiovascular outcomes in T2DM patients [12].”
BackgroundNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G., & Diehl, A. M. (2000) · Nature Medicine · doi:10.1038/79697 · Cited by 673
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall Cells
Isoda, K., Young, J. L., Zirlik, A., MacFarlane, L. A., Tsuboi, N., Gerdes, N., Schönbeck, U., & Libby, P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000201938.78044.75 · Cited by 499
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458
Research works printed but not linked: 24
- Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetes Drafting Group. Diabetologia, 1985. 28 Suppl: p. 615–40. · DOI · Paper page
- Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34. · DOI · Paper page
- Martin-Timon I, et al. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5(4):444–70. · DOI · Paper page
- Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. Prog Biophys Mol Biol. 2011;107(2):248–56. · DOI · Paper page
- Zheng Y, et al. Variants of NLRP3 gene are associated with insulin resistance in Chinese Han population with type-2 diabetes. Gene. 2013;530(1):151–4. · DOI
- Hiramatsu T, et al. Liraglutide improves Glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis. Ther Apher Dial. 2015;19(6):598–605. · DOI
- Chen WR, et al. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2015;170(5):845–54. · DOI
- Inoue T, et al. GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats. Atherosclerosis. 2015;240(1):250–9. · DOI · Paper page
- Ajjan RA, Grant PJ. Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. Diab Vasc Dis Res. 2006;3(3):147–58. · DOI
- Vaez H, et al. Cardioprotective effect of metformin in lipopolysaccharide-induced sepsis via suppression of toll-like receptor 4 (TLR4) in heart. Eur J Pharmacol. 2016;772:115–23. · DOI
- Yabe D, Seino Y. Incretin actions beyond the pancreas: lessons from knockout mice. Curr Opin Pharmacol. 2013;13(6):946–53. · DOI
- Liu MM, et al. Protective effect of glucagon-like peptide-1 analogue on cardiomyocytes injury induced by hypoxia/reoxygenation. Zhonghua Nei Ke Za Zhi. 2016;55(4):311–6.
- Zhang Y, et al. Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-ca-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways. Free Radic Biol Med. 2016;95:278–92. · DOI · Paper page
- Kimura R, et al. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience. 2009;162(4):1212–9. · DOI
- Ladenheim EE. Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther. 2015;9:1867–75. · DOI · Paper page
- Forst T, et al. Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med. 2012;29(9):1115–8. · DOI · Paper page
- Jia J, et al. Neuropharmacological actions of Metformin in stroke. Curr Neuropharmacol. 2015;13(3):389–94. · DOI
- Floyd JS, et al. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. Diabetes Obes Metab. 2015;17(12):1194–7. · DOI
- Fu L, et al. Interaction between metformin and leucine in reducing hyperlipidemia and hepatic lipid accumulation in diet-induced obese mice. Metabolism. 2015;64(11):1426–34. · DOI
- Xu T, et al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2015;38(10):1858–67. · DOI · Paper page
- Garinis GA, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes. 2010;34(8):1255–64. · DOI
- Kashi Z, et al. The role of Metformin response in lipid metabolism in patients with recent-onset type 2 diabetes: HbA1c level as a criterion for designating patients as responders or nonresponders to Metformin. PLoS One. 2016;11(3):e0151543. · DOI
- Croom KF, McCormack PL. Liraglutide: a review of its use in type 2 diabetes mellitus. Drugs. 2009;69(14):1985–2004. · DOI
- Kalra S, et al. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future. Indian J Endocrinol Metab. 2016;20(2):254–67. · DOI · Paper page
Cited by
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0900-7 · Cited by 337
Self-citationGLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
“They comprised 6749 patients (inflammation evaluated in 6560, oxidative stress in 701 patients), included a median (IQR) study population of 60 (33-122) participants, and had a median (IQR) follow-up of 6 months (84-182 days).”
BackgroundAnti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?
Katsiki, N., & Ferrannini, E. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107723 · Cited by 91
Ren, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
Metadata
- Authors
- Liu, Y., Jiang, X., & Chen, X.
- Venue
- Lipids in Health and Disease
- Published
- 2017-12
- Volume
- 16
- Issue
- 1
- Pages
- 227-227
- ISSN
- 1476-511X (ISSN-L)
- OpenAlex
- W2773214455
- Cited by
- 31
- References
- 17
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Endocrinology Department of Tianjin First Center Hospital
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease. https://app.cochat.ai/papers/10.1186/s12944-017-0609-0
- The paper
- Liu, Y., Jiang, X., & Chen, X. (2017). Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease. Lipids in Health and Disease. https://doi.org/10.1186/s12944-017-0609-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.